Edward Conner

Ed Conner, MD is the Chair of the Scientific Advisory Board. Ed currently serves as Chief Medical Officer at Third Harmonic Bio and served as Locanabio’s Chief Medical Officer from 2021–2022. He was formerly the Astellas Gene Therapies Site Lead and Division Head of Gene Therapy Medical & Development and was responsible for leading the global clinical development strategy for Astellas Gene Therapies. He served as the Chief Medical Officer at Audentes Therapeutics which was acquired by Astellas in January 2020. He brings more than 15 years of industry leadership experience in early- and late-stage clinical development across a broad range of disease areas, including rare diseases. Prior to Astellas, Ed was at Sangamo Therapeutics, Inc. where he served as Senior Vice President and Chief Medical Officer and led the clinical development of the company’s pipeline of genomic therapies. Ed also served as Vice President, Global Clinical Development at Ultragenyx Pharmaceutical Inc. where he led the global clinical development efforts for two of the company’s rare disease product candidates earlier in his career Dr. Conner served as Medical Director at Genentech, Inc. Dr. Conner completed his Internal Medicine residency training at the University of Michigan and was a fellow in Clinical Immunology and Allergic Diseases at Johns Hopkins School of Medicine. He earned a BS in Biology, cum laude, from Duke University and his MD from the University of California, San Francisco.